Literature DB >> 15928192

Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.

Mikihiko Kimura1, Hitoshi Tsuda, Daisaku Morita, Eiji Shinto, Takao Tanimoto, Takashi Ichikura, Hidetaka Mochizuki, Osamu Matsubara.   

Abstract

BACKGROUND: Our objective was to examine the utility of endoscopic biopsy specimens in judging the status of epidermal growth factor receptor (EGFR) and c-erbB-2 genes and proteins in the entire tumor.
METHODS: Endoscopic biopsy specimens and specimens of whole representative cut surfaces of corresponding surgically resected tumors were obtained from 14 patients with gastric carcinoma, and immunohistochemistry and fluorescence in situ hybridization were then performed to determine the protein expression and gene amplification profiles, respectively, of EGFR and c-erbB-2 in these biopsy and surgical specimens.
RESULTS: Among the eight endoscopic biopsy specimens obtained from three gastric carcinomas in which EGFR protein overexpression and gene amplification were judged to be positive in the corresponding surgically resected tissue specimens, EGFR overexpression was detected in three specimens (38%), but EGFR amplification was not detected (0%). Among the 19 endoscopic biopsy specimens obtained from five gastric carcinomas in which c-erbB-2 protein overexpression and gene amplification were judged to be positive in the corresponding surgically resected tissue specimens, c-erbB-2 overexpression and amplification (c-erbB-2/CEP17 ratio) were detected in 14 (74%) and 16 (84%) specimens, respectively. All three cases with EGFR overexpression and all five cases with c-erbB-2 overexpression showed intratumor heterogeneity with regard to their EGFR and c-erbB-2 status, respectively.
CONCLUSIONS: The c-erbB-2 status could be adequately assessed not only by examining surgically resected materials, but also by examining multiple endoscopic biopsy specimens. On the other hand, to assess the EGFR status accurately, the use of surgically resected samples appeared to be more reliable than the use of multiple endoscopic biopsy samples.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928192     DOI: 10.1093/jjco/hyi089

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

1.  Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.

Authors:  José Cangiano; Barbara A Centeno; Christopher R Garrett; William Cáceres; Ana de Jesús; Ji-Hyun Lee; Orestes Pavía; Richard Jove; Luis Báez; Daniel M Sullivan; Carlos A Muro-Cacho; Teresita Muñoz-Antonia
Journal:  Dig Dis Sci       Date:  2008-01-26       Impact factor: 3.199

2.  Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule.

Authors:  Hans-Michael Behrens; Viktoria S Warneke; Christine Böger; Nele Garbrecht; Eva Jüttner; Wolfram Klapper; Micaela Mathiak; Ilske Oschlies; Ursula Rudolph; Christiane Stuhlmann-Laeisz; David Trick; Christoph Röcken; Peter Hufnagl
Journal:  Cancer Med       Date:  2014-12-16       Impact factor: 4.452

3.  Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.

Authors:  V S Warneke; H-M Behrens; C Böger; T Becker; F Lordick; M P A Ebert; C Röcken
Journal:  Ann Oncol       Date:  2012-11-08       Impact factor: 32.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.